Applied Therapeutics, Inc. (NASDAQ:APLT) Insider Leslie D. Funtleyder Sells 22,950 Shares

Applied Therapeutics, Inc. (NASDAQ:APLT) insider Leslie D. Funtleyder sold 22,950 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $0.61, for a total transaction of $13,999.50. Following the sale, the insider now directly owns 404,961 shares in the company, valued at approximately $247,026.21. This trade represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Applied Therapeutics Stock Performance

Applied Therapeutics stock traded up $0.00 during midday trading on Friday, hitting $0.61. 1,845,842 shares of the company’s stock were exchanged, compared to its average volume of 5,416,228. The stock has a 50-day moving average price of $0.90 and a two-hundred day moving average price of $5.14. Applied Therapeutics, Inc. has a 52-week low of $0.54 and a 52-week high of $10.62. The company has a market cap of $70.99 million, a P/E ratio of -0.38 and a beta of 1.88.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd purchased a new position in shares of Applied Therapeutics during the 3rd quarter valued at about $149,000. Intech Investment Management LLC bought a new position in Applied Therapeutics during the third quarter valued at approximately $162,000. Algert Global LLC purchased a new position in shares of Applied Therapeutics during the second quarter worth approximately $110,000. The Manufacturers Life Insurance Company bought a new stake in shares of Applied Therapeutics in the 2nd quarter worth approximately $172,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Applied Therapeutics in the 4th quarter valued at $35,000. 98.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Robert W. Baird dropped their price target on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, November 29th. Royal Bank of Canada cut their price target on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a report on Friday, December 20th. Citigroup decreased their price objective on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. UBS Group reaffirmed a “neutral” rating and set a $2.00 target price (down previously from $13.00) on shares of Applied Therapeutics in a report on Monday, December 2nd. Finally, William Blair downgraded shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, December 23rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Applied Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.